Evidence map›Paper›PMID 35310523›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)2022

Early Alzheimer's disease-like reductions in gray matter and cognitive function with aging in nonhuman primates.

Brett M Frye, Suzanne Craft, Thomas C Register, Jeongchul Kim, Christopher T Whitlow, Richard A Barcus, Samuel N Lockhart, Kiran Kumar Solingapuram Sai, Carol A Shively

Abstract read
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Suppressing UBE2N ameliorates Alzheimer's disease pathology through the clearance of amyloid beta.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  12. Structural white matter properties and cognitive resilience to tau pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  13. Review
  14. Article
  15. Review
  16. Alzheimer's Disease: Treatment Strategies and Their Limitations.International journal of molecular sciences · 2022
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Brett M FryeDepartment of Pathology/Comparative Medicine Wake Forest School of Medicine Winston-Salem North Carolina USA.
Suzanne CraftDepartment of Internal Medicine/Gerontology Wake Forest School of Medicine Winston-Salem North Carolina USA.
Thomas C RegisterDepartment of Pathology/Comparative Medicine Wake Forest School of Medicine Winston-Salem North Carolina USA.
Jeongchul KimWake Forest Alzheimer's Disease Research Center Winston-Salem North Carolina USA.
Christopher T WhitlowWake Forest Alzheimer's Disease Research Center Winston-Salem North Carolina USA.
Richard A BarcusWake Forest Alzheimer's Disease Research Center Winston-Salem North Carolina USA.
Samuel N LockhartDepartment of Internal Medicine/Gerontology Wake Forest School of Medicine Winston-Salem North Carolina USA.
Kiran Kumar Solingapuram SaiWake Forest Alzheimer's Disease Research Center Winston-Salem North Carolina USA.
Carol A ShivelyDepartment of Pathology/Comparative Medicine Wake Forest School of Medicine Winston-Salem North Carolina USA.

Funding

Wake Forest Claude D. Pepper OAIC - RenewalP30AG021332 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Denise Kathryn Houston · 2002 to 2026
$36.4M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Wake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUZANNE CRAFT · 2021 to 2026
$24.3M
Vervet Research Colony as a Biomedical ResourceP40OD010965 · OD · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Matthew Jorgensen · 2012 to 2026
$14.6M
Wake Forest Alzheimer's Disease Core CenterP30AG049638 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ESPELAND, MARK ANDREW · 2016 to 2020
$12.2M
Development of an Innovative Vervet (Chlorocebus aethiops sabaeus) Model of Early Alzheimer's-like Neuropathology and SymptomatologyR24AG073199 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI CRAFT, SUZANNE, SHIVELY, CAROL A. · 2021 to 2024
$5.6M
Translational Training in Aging and Alzheimer’s Disease Related DisordersT32AG033534 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI STEPHEN B. KRITCHEVSKY · 2009 to 2026
$3.6M
NCATS NIH HHS UL1 TR001420NIA NIH HHS L30 AG074138NIA NIH HHS P30 AG021332NIA NIH HHS P30 AG049638NIA NIH HHS P30 AG072947NIA NIH HHS R24 AG073199NIA NIH HHS T32 AG033534NIH HHS P40 OD010965
6 · The paper itself

Abstract

Introduction: Age-related neuropathology associated with sporadic Alzheimer's disease (AD) often develops well before the onset of symptoms. Given AD's long preclinical period, translational models are needed to identify early signatures of pathological decline. Methods: Using structural magnetic resonance imaging and cognitive assessments, we examined the relationships among age, cognitive performance, and neuroanatomy in 48 vervet monkeys ( Results: We found negative associations of age with cortical gray matter volume ( Discussion: Cortical gray matter diminishes with age in vervets in regions relevant to AD, which may increase risk of cognitive impairment. This study lays the groundwork for future investigations to test therapeutics to delay or slow pathological decline.

Indexed as

Alzheimer's diseasemagnetic resonance imagingnon‐human primatevervetworking memory

Identifiers

PMID35310523
PMCPMC8918111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.